New! WalletPop

The latest on your money, from news and deals to answers and advice.

Visit Now
WalletPop.com »

Markets

U.S. open in 15 hrs, 8 mins
9,447.11
-508.39
 
5.11%
1,754.88
-108.08
 
5.80%
996.23
-60.66
 
5.74%
104.094
-0.375
 
0.36%
4,605.22
16.03
 
0.35%
10,155.90
-317.19
 
3.03%
16,803.76
0.00
 
0.00%
0.012
 
0.89%
0.05
 
0.05%
90.06
2.25
 
2.56%
882.00
15.80
 
1.82%
Get Quote for:

Array Biopharma and AstraZeneca announce new Ph. 2 development plans for the investigational anti-cancer drug AZD6244

Briefing.com
Posted: 2008-05-16 00:35:00
Co and AstraZeneca (AZN) announce plans for two additional randomized Ph. 2 trials for AZD6244 (ARRY-886). The trials, which will begin during 2H08, will test AZD6244 in combination with a cytotoxic chemotherapeutic agent; one trial will be in melanoma patients and the other in non small cell lung cancer patients. These plans are based upon AZD6244's activity as a single agent in previous monotherapy Phase 2 trials and on data from multiple preclinical studies.

Bookmark:

Recent Comments

Add your own Comments